Canadian Cancer Trials Group Bulletins

General


Recent Publications

Canadian Cancer Trials Group BL.8 (EORTC 30994) - Randomized Phase III Trial Comparing Immediate versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4, and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder

The purpose of this trial was to compare immediate versus deferred cisplatin-based combination chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder.

The results of the trial did not show a significant improvement in overall survival with immediate versus deferred chemotherapy after radical cystectomy and bilateral lymphadenectomy for patients with muscle-invasive urothelial carcinoma. However, the authors indicated the trial was limited in power and that it is possible that some subgroups of patients might still benefit from immediate chemotherapy. They concluded that an updated individual patient data meta-analysis and biomarker research are needed to further elucidate the potential for survival benefit in subgroups of patients.

Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, De Santis M, Th?odore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial (ONLINE). The Lancet Oncology 2014.

http://www.sciencedirect.com/science/article/pii/S147020451471160X
________________________________________

Canadian Cancer Trials Group IND.192 - A Phase II Study of Ridaforolimus in Patients with Metastatic and/or Locally Advanced Recurrent Endometrial Cancer

This phase II study evaluated the single agent tolerability and activity of oral ridaforolimus administered at a dose of 40 mg for 5 consecutive days followed by a 2-day break, in women with recurrent or metastatic endometrial carcinoma who had received no chemotherapy in the metastatic setting. The authors concluded that oral ridaforolimus was reasonably tolerated and demonstrated modest activity in women with recurrent or metastatic endometrial cancers. Potential synergy between mTOR inhibition, angiogenesis and hormonal pathways warrants ongoing evaluation.

Tsoref D, Welch S, Lau S, Biagi J, Tonkin K, Martin LA, Ellard S, Ghatage P, Elit L, Mackay HJ, Allo G, Tsao MS, Kamel-Reid S, Eisenhauer EA, Oza AM. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol 135: 184-9, 2014.

http://www.sciencedirect.com/science/article/pii/S0090825814010749
________________________________________

Canadian Cancer Trials Group MA.21 - A Phase III Adjuvant Trial of Sequenced EC + Filgrastim + Epoetin Alfa Followed by Paclitaxel versus Sequenced AC Followed by Paclitaxel Versus CEF as Therapy for Premenopausal Women and Early Postmenopausal Women Who Have Had Potentially Curative Surgery for Node Positive or High Risk Node Negative Breast Cancer

Liu S, Chapman JA, Burnell M, Levine M, Pritchard K, Whelan T, Rugo H, Albain K, Perez E, Virk S, Barry G, Gao D, O'Brien P, Shepherd L, Nielsen T, Gelmon K. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the Canadian Cancer Trials Group MA.21 phase III chemotherapy trial (ONLINE). Breast Cancer Res Treat 1-10, 2015

http://phttp://dx.doi.org/10.1007/s10549-014-3259-1